Recovery article

IGF-1 LR3 Dosage: 20-50mcg/Day Chart + Calculator (2026)

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you. Where These Numbers Come From IGF-1 LR3 is a research tool and performance compound — it d

By Recovery & Performance Peptides Editorial Team Published July 8, 2026

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

IGF-1 LR3 is a research tool and performance compound — it does not have human clinical trial data for the way it's used in the community.

IGF-1 induces muscle hypertrophy through satellite cell activation and increased protein synthesis in differentiated myofibers (Adams & McCue, 1998). LR3 IGF-1 infusion in animal models stimulates organ growth (adrenals, gut, kidneys, spleen) while suppressing endogenous IGF-1 and IGFBP levels (Bastian et al., 1993).

The LR3 modification provides a 20-30 hour half-life (vs minutes for native IGF-1), reduced IGFBP binding, and approximately 2-3x potency. Community doses of 20-80 mcg daily are extrapolated from animal research scaling, decades of bodybuilding experience, potency considerations, and risk management balancing anabolic effects against hypoglycemia (Florini et al., 1996).

Stacking Protocols

MK-677

20-40 mcg post-workout

12.5-25 mg PM

Growth stack

BPC-157

250-500 mcg

Growth + recovery

CJC-1295/Ipamorelin

20-30 mcg post-workout

CJC/Ipa

Per protocol

Comprehensive GH/IGF-1 axis

Community protocols describe running IGF-1 LR3 alone first and lowering LR3 doses to 20-30 mcg when stacking. Community sources emphasize watching blood sugar closely, since multiple compounds may compound hypoglycemia risk, and describe blood work (IGF-1, glucose, insulin, HbA1c) as essential.

Side Effects & Safety

Hypoglycemia (most immediate risk) — shaking, dizziness, sweating, confusion; community sources describe keeping fast-acting carbs available

Organ growth — gut distension and cardiomegaly possible with prolonged, high-dose use

Jaw and hand growth — subtle acromegaly-like changes with chronic use

Cancer risk — chronically elevated IGF-1 is associated with increased cancer risk in epidemiological studies

Joint pain — connective tissue changes, water retention

Fatigue/lethargy — common, especially initially

Injecting before sleep — community sources warn against this, as hypoglycemia during sleep is dangerous

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). Once IGF-1 LR3 is reconstituted, the conversion from a target dose to syringe units depends on the chosen dilution.

The two reconstitution ratios most often described in community protocols are below.

Reconstitution A: 1 mg vial + 1 mL BAC water (1 mg/mL) — the standard dilution from the Quick Reference above.

25 mcg

0.025 mL

2.5 units

50 mcg

0.05 mL

5 units

75 mcg

0.075 mL

7.5 units

100 mcg

0.1 mL

10 units

Reconstitution B: 1 mg vial + 3 mL BAC water (333 mcg/mL) — more BAC water for larger, easier-to-measure draws.

0.15 mL

15 units

0.225 mL

22.5 units

0.3 mL

30 units

These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.

Core Supplies for This Protocol

The three essentials for running any reconstituted injectable: cold storage, accurate syringes, and metabolic tracking.

Cooluli Classic 4L Mini Fridge

Compact thermoelectric mini-fridge with heat/cool toggle. The most-mentioned dedicated peptide-storage fridge in research community sources — fits ~20 vials and runs quietly.

BD Ultra-Fine 31G 0.3cc 5/16" Insulin Syringes (Box of 90)

0.3cc 31G syringes — each gradation marks 1 unit (vs 2 units on 1cc), making sub-50-unit peptide doses accurate. BD Ultra-Fine is the most widely-cited brand in peptide community sources.

CONTOUR NEXT GEN Glucose Meter All-In-One Kit

Ascensia's CONTOUR NEXT GEN — the most clinically-validated home glucose meter. Includes 20 test strips + lancing device. Tracks the blood-sugar response GLP-1 users care about, especially during dose escalation.

As an Amazon Associate, The Peptide Catalog earns from qualifying purchases.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

COACH'S BOARD / KEY POINTS

IGF-1 LR3 has a half-life of 20–30 hours due to reduced IGFBP binding, meaning it accumulates with daily dosing and reaches steady state after 3–5 days.
Research protocols typically use 20–100 mcg per day, with 40–60 mcg representing the optimal range for sustained anabolic signaling without rapid receptor desensitization.
Subcutaneous administration produces 70–80% bioavailability with a time to peak concentration of 4–6 hours. Timing of endpoint measurements must account for this delay.
Reconstituted IGF-1 LR3 remains stable for 14–21 days when refrigerated at 2–8°C; temperature excursions above 8°C cause irreversible degradation that is not visually detectable.
Every-other-day dosing at 40–50 mcg may preserve IGF-1R expression longer than daily dosing at 20–25 mcg in chronic protocols lasting more than two weeks.
Dose IGF-1 LR3 in the fasted state when possible. Elevated insulin competes for receptor binding and alters the signaling profile, introducing variability in metabolic endpoints.

SOURCE / realpeptides.co ↗

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

IGF-1 LR3 Dosage, Reconstitution & Mixing Trends

Explore IGF-1 LR3 dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions. IGF-1 LR3 is a long-acting variant of insulin-like growth factor 1, engineered with an N-terminal extension that significantly extends its half-life versus native IGF-1. This data shows the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when reconstituting IGF-1 LR3. 320 IGF-1 LR3 reconstitution calculations have been logged by the WPA community. The most common dose entered is 50mcg (121 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 1mg (252 sessions). The most common dosing frequency is daily (7x/week) (31 logged protocols), followed by 5x/week (10). World Peptide Association aggregates anonymized peptide calculator data to show real-world dosing trends, reconstitution volumes, and vial size preferences across the research peptide community. All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.

Question drills

Open a question for its connected answer.

01What If I Start at 100mcg Daily Because I Want Faster Results?+

You'll likely hit a plateau within 10–14 days as IGF-1 receptors downregulate in response to sustained high-level stimulation. Research shows peak mTOR activation occurs at 50ng/mL tissue concentration. Doubling IGF-1 LR3 dose doesn't double signaling output. Start at 40mcg and assess response over two weeks before increasing incrementally.

SOURCE / realpeptides.co ↗

02What If I Experience Persistent Joint Pain After Starting IGF-1 LR3?+

Reduce the dose by 30–40% immediately and assess whether symptoms resolve within 48–72 hours. Joint discomfort (arthralgias) occurs in approximately 15–25% of research subjects at doses above 80 mcg daily and is thought to result from increased synovial fluid production and connective tissue water retention mediated by IGF-1 receptor activation in joint capsules. If pain persists at reduced dose, discontinue for 5–7 days and restart at 20 mcg with slower titration. Some individuals exhibit heightened sensitivity to IGF-1 signaling that requires more conservative dosing schedules.

SOURCE / realpeptides.co ↗

03What If Baseline Endogenous IGF-1 Levels Are Already Elevated?+

Reduce IGF-1 LR3 dosage to the lower end of the therapeutic range (20–30 mcg daily). Endogenous IGF-1 and exogenous IGF-1 LR3 compete for the same receptor pool. High baseline IGF-1 means fewer unoccupied receptors available for the LR3 variant to bind. Administering standard doses (40–60 mcg) when endogenous IGF-1 is already at 250+ ng/mL produces minimal additional proliferative effect because receptor saturation is approached. Monitor serum IGF-1 levels before initiating protocols. Baseline above 200 ng/mL warrants dose reduction or extended dosing intervals.

SOURCE / realpeptides.co ↗

04What If I Need to Calculate IGF-1 LR3 Dosage for a Multi-Week Study with Escalating Doses?+

Design your reconstitution strategy around your highest planned dose to maintain consistent injection volumes throughout the study. If your protocol escalates from 20mcg to 80mcg over four weeks, reconstitute all vials at the same concentration (500mcg/mL for 1mg in 2mL) so that dose changes require only syringe unit adjustments, not concentration recalculations. Week 1 at 20mcg = 4 units, Week 2 at 40mcg = 8 units, Week 3 at 60mcg = 12 units, Week 4 at 80mcg = 16 units. Same concentration, same calculation method, reduced operator error. Label each reconstituted vial with concentration, reconstitution date, and expiration date (28 days post-mixing). If your study duration exceeds 28 days, calculate total peptide required, divide by vial size, and stagger reconstitution dates so that no vial is used beyond its 28-day stability window. Temperature-logging during storage is non-negotiable for multi-week studies. A single overnight refrigerator failure can invalidate weeks of data collection if the peptide denatures.

SOURCE / realpeptides.co ↗

05What If Satellite Cell Activation Doesn't Occur at Standard Dosages?+

Verify peptide purity and reconstitution protocol first. IGF-1 LR3 degrades rapidly if exposed to temperatures above 8°C or reconstituted with standard saline instead of bacteriostatic water. Request third-party HPLC verification from your supplier. If purity is confirmed, assess timing relative to muscle damage: IGF-1 LR3 cannot activate quiescent satellite cells without upstream mechanical or inflammatory signals. Administer within 2 hours of eccentric training, injury induction, or chemical myotoxin application. If both factors are confirmed, consider receptor priming with a 72-hour washout followed by re-administration at 50mcg.

SOURCE / realpeptides.co ↗

Product & matchup locker

Linked catalog and comparison files.

Comparison

Reading the Insulin Syringe (Units vs mL)

A U-100 insulin syringe is marked in "units," not milliliters. On a U-100 scale, 100 units equals 1 mL, so 1 unit equals 0.01 mL. The entire barrel of a 1 mL syringe runs from 0 t…

Where These Numbers Come From

Stacking Protocols

Side Effects & Safety

mg to Units Conversion

Core Supplies for This Protocol

Cooluli Classic 4L Mini Fridge

BD Ultra-Fine 31G 0.3cc 5/16" Insulin Syringes (Box of 90)

CONTOUR NEXT GEN Glucose Meter All-In-One Kit

Reading the Insulin Syringe (Units vs mL)

IGF-1 LR3 Dosage Protocol | PeptideDosages.com